Johnson & Johnson (JNJ)vsPACS Group, Inc. (PACS)
JNJ
Johnson & Johnson
$231.29
+0.82%
HEALTHCARE · Cap: $567.28B
PACS
PACS Group, Inc.
$37.77
-1.23%
HEALTHCARE · Cap: $5.74B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 1674% more annual revenue ($96.36B vs $5.43B). JNJ leads profitability with a 21.8% profit margin vs 4.5%. PACS appears more attractively valued with a PEG of 1.07. PACS earns a higher WallStSmart Score of 60/100 (C+).
JNJ
Buy57
out of 100
Grade: C
PACS
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-67.8%
Fair Value
$136.12
Current Price
$231.29
$95.17 premium
Intrinsic value data unavailable for PACS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Earnings expanding 194.1% YoY
Every $100 of equity generates 24 in profit
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
4.5% margin — thin
Distress zone — elevated risk
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : PACS
The strongest argument for PACS centers on EPS Growth, Return on Equity. Revenue growth of 11.2% demonstrates continued momentum. PEG of 1.07 suggests the stock is reasonably priced for its growth.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : PACS
The primary concerns for PACS are Profit Margin, Altman Z-Score, Debt/Equity. Debt-to-equity of 3.38 is elevated, increasing financial risk. Thin 4.5% margins leave little buffer for downturns.
Key Dynamics to Monitor
JNJ profiles as a mature stock while PACS is a value play — different risk/reward profiles.
PACS is growing revenue faster at 11.2% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
PACS scores higher overall (60/100 vs 57/100) and 11.2% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →PACS Group, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
PACS Group, Inc. is a leading technology solutions provider focused on enhancing operational efficiency through a suite of innovative software and hardware systems tailored for diverse industries. The company places a strong emphasis on research and development, positioning itself to capitalize on emerging technological trends and drive digital transformation initiatives. With a strong portfolio of strategic partnerships and a solid market presence, PACS Group is strategically poised to sustain and enhance its competitive advantage, presenting a compelling investment opportunity for institutional investors looking to tap into growth within the dynamic technology sector.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?